<DOC>
	<DOCNO>NCT02051946</DOCNO>
	<brief_summary>The purpose study identify whether injection study drug ( ethacrynic acid ) use investigational Retroject device able low eye pressure patient advance glaucoma . 20 patient advanced glaucoma visual acuity le 20/200 intraocular pressure ( IOP ) &gt; 20mmHg maximum medical therapy ask participate study . The first five patient Retroject device place eye 30 second remove . Assuming issue , place eye one minute . The second group patient ( 3 total ) Retroject device place eye injection ethacrynic acid episcleral vein . The third group patient ( 12 total ) Retroject device place eye randomize 2:1 ratio receive either ethacrynic acid injection balance salt solution injection . All 20 patient return intraocular pressure measurement day 1 , 2 , 3 , 7 well 6 week injection . In addition , patient undergo pre post intervention corneal endothelial assessment ( endothelial cell count , shape analysis , pachymetry ) . Potential safety issue unlikely include bleed , infection , pain , ototoxicity , temporary permanent loss vision .</brief_summary>
	<brief_title>Novel Drug Delivery Technique Via Retroject Device</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ethacrynic Acid</mesh_term>
	<criteria>age 55 year old sex IOP &gt; 20 mmHg maximal treatment &lt; 20/200 visual acuity willing sign inform consent form monocular patient bleed disorder patient anticoagulant antiplatelet medication patient prior laser surgery ( SLT ALT )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>novel drug delivery technique glaucoma patient</keyword>
</DOC>